$ImmunityBio, Inc.(IBRX)$ I closed further positions on IBRX! The gift that keeps on giving!
Cheers IBRX! Hopefully some of you Tigers 🐅🐅🐅 followed me in these trades for huge profits! Swimming in the 💰💰💰💸💸💸🤑🤑🤑 today! still further upside but it hit my initial target 🎯. Please follow me for further profitable short-term trades❣️
Happy trading ahead, BC! 🍀
@Tiger_comments @Daily_Discussion @TigerPicks @TigerObserver @TigerGPT @TigerPM @TigerStars
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
ImmunityBio, Inc. (IBRX) is a clinical-stage biotechnology company that focuses on developing therapies and vaccines to enhance the immune system's ability to fight cancer and infectious diseases. Here is some information about the company:
Business Profile: ImmunityBio develops immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company is based in San Diego, California, and operates in the United States and Europe.
Business Revenue: Based on the 2023 annual report, Europe's revenue accounted for 95.02% of the total, while the United States' revenue accounted for 4.98%.
Executive Information: The key executives of ImmunityBio include Patrick Soon-Shiong (Chairman of the Board of Directors, Chief Executive Officer), Richard J. Tajak (Chief Financial Officer), Barry J. Simon (President, Chief Administrative Officer, Director), and Sonja Nelson (Chief Accounting Officer).
Shareholder Information: The major shareholders of ImmunityBio include Patrick Soon-Shiong (shareholding ratio: 41.80%), California Capital Equity, LLC (shareholding ratio: 19.70%), NantWorks, LLC (shareholding ratio: 14.15%), The Vanguard Group, Inc. (shareholding ratio: 1.99%), and BlackRock, Inc. (shareholding ratio: 1.64%).
Stock Information: The company's stock code is IBRX.
Contact Information: ImmunityBio's address is 3530 John Hopkins Court, San Diego, California, United States. You can contact them at 844 696 5235.
Recent News: According to recent news articles, ImmunityBio announced the initiation of dosing in a Phase 1 clinical trial for its novel CD19 t-haNK cell therapy, which aims to evaluate the safety and preliminary efficacy of the therapy in patients with relapsed or refractory B-cell malignancies. The company also dosed the first patients in a Phase 1 trial assessing its CAR-NK cellular therapy as a potential treatment for non-Hodgkin's lymphoma. These developments have positively impacted the stock price.
You can find more information about ImmunityBio, Inc. and its recent news in the following articles:
ImmunityBio Shares Jump After First Patients Dosed in Phase 1 Study for Potential Non-Hodgkin's Lymphoma Treatment
Stock Track | ImmunityBio Soars on Positive Trial Update for Cancer Treatment
ImmunityBio Extends Gains After Trial Update
ImmunityBio: Moving The Needle
Please note that the above information is for reference purposes only and does not constitute investment advice. Investing in stocks carries risks, and it is important to conduct thorough research and analysis before making any investment decisions.